Alexander Jordan, MD
Assistant Professor of Medicine (Medical Oncology & Hematology)Cards
About
Research
Publications
2026
A context-augmented large language model for accurate precision oncology medicine recommendations
Jun H, Tanaka Y, Johri S, Camp S, Bao E, Carvalho F, Gui D, Jordan A, Labaki C, Martin S, Nagy M, O'Meara T, Pappa T, Pimenta E, Saad E, Yang D, Gillani R, Tewari A, Reardon B, Van Allen E. A context-augmented large language model for accurate precision oncology medicine recommendations. Cancer Cell 2026, 44: 676-685.e4. PMID: 41544626, PMCID: PMC12811686, DOI: 10.1016/j.ccell.2025.12.017.Peer-Reviewed Original Research
2024
Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer
Singh H, Xiu J, Kapner K, Yuan C, Narayan R, Oberley M, Farrell A, Surana R, Huffman B, Perez K, Cleary J, Jordan A, Costa A, Williams H, Raghavan S, Weinberg B, Pishvaian M, Shroff R, Goel S, Dougan S, Nowak J, Spetzler D, Sledge G, Wolpin B, Aguirre A. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clinical Cancer Research 2024, 30: 4932-4942. PMID: 39283131, PMCID: PMC12267046, DOI: 10.1158/1078-0432.ccr-24-1164.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDeoxycytidineFemaleFluorouracilGemcitabineGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsHumansIrinotecanKaplan-Meier EstimateLeucovorinMaleMiddle AgedMutationOxaliplatinPaclitaxelPancreatic NeoplasmsPrognosisProto-Oncogene Proteins p21(ras)ConceptsSB tumorsTranscriptional subtypesPancreatic cancerNab-paclitaxelOutcome cohortPredictors of bad outcomeBiomarker cohortCaris Life SciencesFirst-line chemotherapyRates of KRASProfile of pancreatic cancerEvidence of epithelial-mesenchymal transitionPrognostic of outcomeCox proportional hazards regressionKaplan-Meier curvesOverall survival timeShorter overall survival timeMutant KRAS allelesAssociated with shorter overall survival timeProportional hazards regressionChemotherapy regimenMetastatic diseaseBasal tumorsEpithelial-mesenchymal transitionSC tumorsMechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
Dilly J, Hoffman M, Abbassi L, Li Z, Paradiso F, Parent B, Hennessey C, Jordan A, Morgado M, Dasgupta S, Uribe G, Yang A, Kapner K, Hambitzer F, Qiang L, Feng H, Geisberg J, Wang J, Evans K, Lyu H, Schalck A, Feng N, Lopez A, Bristow C, Kim M, Rajapakshe K, Bahrambeigi V, Roth J, Garg K, Guerrero P, Stanger B, Cristea S, Lowe S, Baslan T, Van Allen E, Mancias J, Chan E, Anderson A, Katlinskaya Y, Shalek A, Hong D, Pant S, Hallin J, Anderes K, Olson P, Heffernan T, Chugh S, Christensen J, Maitra A, Wolpin B, Raghavan S, Nowak J, Winter P, Dougan S, Aguirre A. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discovery 2024, 14: 2135-2161. PMID: 38975874, PMCID: PMC11528210, DOI: 10.1158/2159-8290.cd-24-0177.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaKRAS inhibitionAcquired ResistanceNon-genetic mechanismsMouse modelAmplification of KRASCombination therapy strategiesResistance to therapyMultiple preclinical modelsCombination therapy approachPancreatic ductal adenocarcinoma cell linesEpithelial-to-mesenchymal transitionPI3K-AKT-mTORP48-CreTumor controlTumor regressionPDX modelsPreclinical modelsClinical efficacyPancreatic cancerDuctal adenocarcinomaTherapy strategiesDrug resistanceCombined treatmentKRAS inhibitors
2022
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Huffman B, Ellis H, Jordan A, Freed-Pastor W, Perez K, Rubinson D, Sethi N, Singh H, Surana R, Wolpin B, Aguirre A, Cleary J. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers 2022, 14: 6223. PMID: 36551707, PMCID: PMC9776746, DOI: 10.3390/cancers14246223.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaAggressive biologyBRCA2Targeted therapyBiology of pancreatic ductal adenocarcinomaResistant to cytotoxic chemotherapyPancreatic ductal adenocarcinoma tumorsMetastatic pancreatic adenocarcinomaMolecular targeted therapySubpopulation of patientsTargetable genetic alterationsTreatment of patientsManagement of patientsCytotoxic chemotherapySystemic therapyMismatch repair deficiencyPancreatic adenocarcinomaDuctal adenocarcinomaGenetic alterationsPARP inhibitionEffective therapyG12C inhibitorsMolecular profilingTherapy
2021
COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system
Fu C, Stoeckle J, Masri L, Pandey A, Cao M, Littman D, Rybstein M, Saith S, Yarta K, Rohatgi A, Makarov D, Sherman S, Morrissey C, Jordan A, Razzo B, Theprungsirikul P, Tsai J, Becker D. COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system. Cancer 2021, 127: 3466-3475. PMID: 34096048, PMCID: PMC8239692, DOI: 10.1002/cncr.33657.Peer-Reviewed Original ResearchConceptsHistory of cancerRisk of deathActive cancerCancer historyMorbidly obese body mass indexCancer diagnosisRisk factors associated with severe outcomesCity Health Care SystemHospitalized patientsHealth care systemObese body mass indexActive cancer diagnosisCancer-directed therapyFactors associated with severe outcomesHigh riskBody mass indexMultivariate logistic regressionHigher risk of deathMedical center recordsCare systemDescriptive statisticsAssociated with deathMass indexCOVID-19COVID-19 outcomes
2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
Ko A, Jordan A, Tooker E, Lacey S, Chang R, Li Y, Venook A, Tempero M, Damon L, Fong L, O'Hara M, Levine B, Melenhorst J, Plesa G, June C, Beatty G. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy 2020, 28: 2367-2378. PMID: 32730744, PMCID: PMC7647666, DOI: 10.1016/j.ymthe.2020.07.017.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaT cell immunosurveillanceT cellsB cellsCART-19Chimeric antigen receptor-modified T cellsConcomitant deliveryInfiltrating pancreatic ductal adenocarcinomasReceptor-modified T cellsChimeric antigen receptorDose-limiting toxicityAutologous T cellsMetastatic pancreatic cancerPreclinical cancer modelsNormal B cellsDays post-infusionStable diseaseCART cellsDual-targetingAntigen receptorPancreatic cancerPost-infusionCancer modelsDuctal adenocarcinomaTumor cellsImmunotherapy in hepatocellular carcinoma: Combination strategies
Jordan A, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. World Journal Of Meta-Analysis 2020, 8: 190-209. DOI: 10.13105/wjma.v8.i3.190.Peer-Reviewed Original ResearchOxidative Phosphorylation Promotes Primary Melanoma Invasion
Salhi A, Jordan A, Bochaca I, Izsak A, Darvishian F, Houvras Y, Giles K, Osman I. Oxidative Phosphorylation Promotes Primary Melanoma Invasion. American Journal Of Pathology 2020, 190: 1108-1117. PMID: 32142731, PMCID: PMC7237828, DOI: 10.1016/j.ajpath.2020.01.012.Peer-Reviewed Original ResearchConceptsOxidative phosphorylationPrimary melanomaTranscriptome analysisEarly progressionRadial to vertical growthMelanoma cellsConstitutive activationProliferative marker Ki-67Melanoma invasionGenes associated with oxidative phosphorylationPrimary melanoma specimensRadial growth phase melanoma cellsRibosomal protein S6 kinase A1Growth of primary melanomaInvasive growthZebrafish melanoma modelUtilization of glutamineHuman melanoma cellsTumor thicknessMetastatic diseaseDermal invasionKi-67Melanoma modelMelanoma specimensMalignant melanoma
2019
Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines
Xu J, Sai H, Li Y, Jordan A, McGettigan S, Chen J, Bedoya F, Fraietta J, Gladney W, Melenhorst J, Beatty G. Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 656-658.e6. PMID: 31398492, PMCID: PMC6889367, DOI: 10.1016/j.jcmgh.2019.07.008.Peer-Reviewed Original Research
2014
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Grabiner B, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck A, Sabatini D. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity. Cancer Discovery 2014, 4: 554-563. PMID: 24631838, PMCID: PMC4012430, DOI: 10.1158/2159-8290.cd-13-0929.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticCell Line, TumorDatabases, FactualHEK293 CellsHeLa CellsHumansMAP Kinase Signaling SystemMCF-7 CellsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceMice, NudeMultiprotein ComplexesMutationNeoplasmsNeoplasms, ExperimentalProtein Kinase InhibitorsSirolimusTOR Serine-Threonine KinasesXenograft Model Antitumor AssaysConceptsC-terminal halfMTOR mutationsResistance to nutrient deprivationTumor genome sequencing dataGenome sequence dataPI3K-AKT-mTOR signaling axisSensitive to rapamycinMTOR complex 1MTOR inhibitor DEPTORSequence dataCancer cell linesNutrient deprivationRapamycin sensitivityMultiple cancer typesComplex assemblyIn vivo xenograftsComprehensive catalogMTOR pathway mutationsPI3K-AKT-mTORPathway mutationsMutationsMTOR kinaseSignaling AxisPathway-dependentCell lines
Clinical Care
Overview
Clinical Specialties
Gastrointestinal Oncology
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2025
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2020
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.